The administration of the nutraceutical compound Migratens® modulates the immune response in individuals with fibromyalgia

Abstract

Objectives: The aim of this study was to assess the response to Migratens® (α-lipoic acid, magnesium bisglycinate, l-tryptophan, vitamin D3, vitamin B2, coenzyme Q10, niacin) in both innate and adaptive immune cells in individuals affected by fibromyalgia (FM). Methods: Twenty individuals with FM were enrolled in the study and were treated with Migratens®. Blood samples were collected before and after 3 months of treatment. Cytokine production and cell frequency of T helper (Th), γδ T cells and Mucosal-associated invariant T (MAIT) cells were evaluated by flow cytometry. Participants underwent complete clinical evaluation at each timepoint and correlations with clinical scores of disease activity were performed. Results: Participants treated with Migratens® showed a significant improvement in all clinical scores evaluated. In participants treated with the nutraceutical compound Migratens®, a reduction in IFN-γ spontaneous release from both adaptive and innate T cells was evidenced. IL-9 from Th, and to a lesser extent from γδ T cells, was also significantly reduced, while IL-4 from Th increased following treatment. No important effects were highlighted for IL-17, IL-5 and IL-13 release. Conclusions: The administration of Migratens® to individuals with FM seems to modulate the production of cytokines through a reduction in proinflammatory molecules, such as IFN-γ and IL-9, and a concomitant increase in anti-inflammatory agents, such as IL-4, thus helping to restore the homeostasis of the immune system in FM. Our results suggest that the nutraceutical approach with Migratens® could be a viable and effective treatment in the complex management of individuals with FM.